| The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals. | |
| | |
MedLine Citation:
|
PMID: 19968507 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Protease inhibitors potently suppress HIV viral load but are often associated with metabolic disturbances such as dyslipidemias and lipodystrophy. In addition to exercise, diet modification and anti-lipid therapies, one potential management strategy for HIV-positive patients with dyslipidemia is to switch any antiretrovirals that may be exacerbating the condition to more lipid-neutral drugs. The SWITCHMRK studies examined the effects of substituting lopinavir/ritonavir, a protease inhibitor known to cause dyslipidemias, with the integrase inhibitor raltegravir. Participants who switched from lopinavir/ritonavir to raltegravir experienced an improvement in cholesterol and triglycerides at 12 weeks; however, a large proportion of patients in the raltegravir arms did not maintain HIV virologic suppression at less than 50 copies/ml at week 24. Further analyses are underway to determine why more patients in the raltegravir arms experienced increased virologic failure and to determine whether switching lopinavir/ritonavir with raltegravir may be appropriate for specific subgroups of patients. |
| | |
Authors:
|
Jennifer Cocohoba |
Related Documents
:
|
3100417 - Molecular pathology and immunology of factor viii (hemophilia a and factor viii inhibit... 17503547 - Hiv integrase inhibitors as therapeutic agents in aids. 14640387 - Effects of metformin or gemfibrozil on the lipodystrophy of hiv-infected patients recei... 16135977 - Epidural spinal lipomatosis with acute onset of paraplegia in an hiv-positive patient t... 11261787 - Cd86 expression correlates with amounts of hiv produced by macrophages in vitro. 8561977 - Early biopsy versus empiric treatment with delayed biopsy of non-responders in suspecte... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of anti-infective therapy Volume: 7 ISSN: 1744-8336 ISO Abbreviation: Expert Rev Anti Infect Ther Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-12-08 Completed Date: 2010-02-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101181284 Medline TA: Expert Rev Anti Infect Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1159-63 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacy, University of California San Francisco School of Pharmacy, 521 Parnassus Avenue, C-152, Box 0622, San Francisco, CA 94143, USA. cocohobaj@pharmacy.ucsf.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
HIV Infections
/
drug therapy* HIV Protease Inhibitors / adverse effects, therapeutic use* Humans Pyrimidinones / adverse effects, therapeutic use* Pyrrolidinones / adverse effects, therapeutic use* Randomized Controlled Trials as Topic Treatment Outcome Viral Load / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/HIV Protease Inhibitors; 0/MK 0518; 0/Pyrimidinones; 0/Pyrrolidinones; 192725-17-0/lopinavir |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Overexpression of IL-13 in Patients With Bladder Cancer.
Next Document: Lancet conference: influenza in the Asia-pacific and the international scientific symposium on influ...